Coral Laboratories Ltd.
Snapshot View

431.25 +6.50 ▲1.5%

23 July 2021, 04:00:00 P.M.
Volume: 1,351

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.corallab.com
Financial Indicators
Market Cap 153.84 Cr.
Earnings per share (EPS) 37.94 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 11.35 Trailing Twelve Months Ending 2021-03
Industry PE 35.17 Trailing Twelve Months Ending 2021-03
Book Value / Share 382.48 Trailing Twelve Months Ending 2021-03
Price to Book Value 1.13 Calculated using Price: 430.60
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 0.36 Cr. 3,572,600 Shares
FaceValue 10
Company Profile

Coral Laboratories was founded in 1994. The company is equipped with an ultra modern manufacturing unit in the state of Gujarat, Daman & today is a force to reckon with in the pharmaceutical industry; a fact which has been endorsed by the WHO GMP certification issued by the Food & Drugs Control Administration and ISO 9001-2000 Quality certification issued by American Quality Assessors.

The Company with deep basket of products is focused in hostlic human welfare and is bringing planfort to people with its Inflammatory, Bacterial, Biotic, Protein deficiencies & Skin conditions. Medicines across the nation, manufactured under the ZEST group & MOXBRO group being the most popular brands across the nation, manufactured by the company.Coral Laboratories has been following a steady growth path on the pillars of its philosophy of “Total Quality Management” & “Quality Products at Affordable Prices”.

The state-of-the art manufacturing facilities meet the stringent and over changing quality requirement of the most discerning buyers. Coral has a multi location manufacturing facilities based on Baroda, Daman & Vasai for strategies convenience. The facilities carrying WHO-GMP & ISO 9001 : 2000 certification. The new manufacturing facilities under expansion to have UK – MHRA and US– FDA certification.

Coral has one of the best quality control laboratory in indian pharmaceuticals industry equipped with latest and sensitive laboratory instruments.

Product range of the company includes:

  • Capsules & Dry Syrups
  • Tablets
  • Liquid Orals
  • Kits
  • Ointment & Cream
  • Injection – Eye – Ear Drops
  • Others

Achievements/ recognition:

  • WHO GMP certification issued by the Food & Drugs Control Administration
  • ISO 9001-2000 Quality certification issued by American Quality Assessors.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+1.53%
1 Week
+1.67%
1 Month
-11.81%
3 Month
+15.76%
6 Month
+53.63%
1 Year
+100.16%
2 Year
+125.84%
5 Year
-9.34%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 15.85 14.76 16.72 17.46 19.18 18.17 11.04 8.88 6.22
Return on Capital Employed (%) 20.18 18.70 21.24 22.22 26.93 27.23 15.91 13.44 7.86
Return on Assets (%) 12.49 11.25 13.25 14.40 15.32 14.77 9.17 7.40 5.09

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 38 44 51 59 70 109 116 114 116
Non Curr. Liab. 1 1 1 1 1 3 4 4 4
Curr. Liab. 10 14 9 12 18 19 20 18 25
Minority Int.
Equity & Liab. 49 58 61 72 89 131 140 136 144
Non Curr. Assets 25 24 23 22 25 58 68 52 48
Curr. Assets 24 34 37 50 65 74 72 84 96
Misc. Exp. not W/O
Total Assets 49 58 61 72 89 131 140 136 144

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 40 42 51 59 77 95 92 91 71
Other Income 1 1 1 3 3 3 4 5 6
Total Income 41 43 52 62 80 99 97 96 76
Total Expenditure -32 -34 -41 -47 -61 -72 -77 -79 -65
PBIDT 8 9 11 15 19 27 20 18 11
Interest 0 0 0 0 0 0 0 0 0
Depreciation -1 -1 -1 -3 -2 -2 -2 -2 -2
Taxation -1 -2 -2 -3 -5 -8 -6 -5 -2
Exceptional Items 0
PAT 6 6 8 10 12 16 12 10 7

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 3 0 1 0 5 11 13 -1 -4
Cash Fr. Inv. 0 0 1 0 -3 -10 -13 3 -2
Cash Fr. Finan. 0 0 0 0 0 0 -3 -1 4
Net Change 3 1 2 0 2 1 -2 1 -2
Cash & Cash Eqvt 4 5 7 7 9 4 2 3 1

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 71.51 71.51 71.51 71.51 71.51 71.51 71.51 71.51 71.51
Public 28.49 28.49 28.49 28.49 28.49 28.49 28.49 28.49 28.49
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Mon, 19 Jul 2021
Disclosure Under Reg. 23(9) Of SEBI (LODR) Regulations 2015
Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements Regulations) 2015 we hereby submit disclosure of Related Party Transactions for the half year ended March 31 2021 in accordance with the applicable Accounting Standards.

Request you to take the same on record and acknowledge.
Mon, 12 Jul 2021
Shareholding for the Period Ended June 30 2021
Coral Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here
Fri, 09 Jul 2021
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Please find attached herewith Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 furnished by M/s. Link Intime India Private Limited the Registrar and Share Transfer Agent of the Company for the quarter ended June 30 2021.

You are requested to take the same on record.

Technical Scans View Details

Fri, 23 Jul 2021
Stock Outperforming Benchmark Index in both 1 Week and 3 Month Stock Outperforming Benchmark Index in both 1 Week and 3 Month
Stock Outperforming Sectoral Index in both 1 Week and 3 Month Stock Outperforming Sectoral Index in both 1 Week and 3 Month
Both SRS And ARS Above Zero Both SRS And ARS Above Zero
Stochastic Reversing from Oversold Zone from Below Stochastic Reversing from Oversold Zone from Below
NR 4 NR 4

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 166,513.85 694.00 +1.0%
Divi's Laboratories Ltd. 128,088.59 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. 90,175.51 5,420.50 +0.7%
Cipla Ltd. 76,510.04 948.50 -0.1%
Cadila Healthcare Ltd. 62,965.29 615.05 -0.9%
Aurobindo Pharma Ltd. 56,484.48 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. 56,291.69 3,915.00 -1.8%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 57.34 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 64.55 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.21 5,420.50 +0.7%
Cipla Ltd. Consolidated 2021-03 31.81 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 29.51 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.59 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 374.38 3,915.00 -1.8%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.58 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 13.78 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.15 5,420.50 +0.7%
Cipla Ltd. Consolidated 2021-03 4.17 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 4.85 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.58 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.25 3,915.00 -1.8%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 0.18 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 3,915.00 -1.8%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 10.09 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 3,915.00 -1.8%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 12.53 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 3,915.00 -1.8%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 17,131.99 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 3,915.00 -1.8%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 1,546.98 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 3,915.00 -1.8%